Stay updated on Tivozanib vs Sorafenib in Refractory RCC Clinical Trial

Sign up to get notified when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T23:39:20.000Z thumbnail image
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    9 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, representing an update in the study record of a Phase 3 clinical trial comparing tivozanib to sorafenib in participants with refractory advanced renal cell carcinoma (RCC). This change may impact the evaluation of progression free survival, overall survival, objective response rate, and the duration of response, as well as safety and tolerability outcomes.
    Difference
    0.1%
    Check dated 2024-06-06T14:44:44.000Z thumbnail image
  7. Check
    23 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants, specifying that they must be 18 years or older with metastatic RCC who have failed 2 or 3 prior systemic regimens, among other health conditions and prior treatments.
    Difference
    10%
    Check dated 2024-05-22T21:15:21.000Z thumbnail image
  8. Check
    45 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:56:44.000Z thumbnail image

Stay in the know with updates to Tivozanib vs Sorafenib in Refractory RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.